Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Researchers combine genetic and clinical factors in new VTE risk score

Publish date:: July 31, 2019

Key clinical point: A genetic and clinical risk factor score may offer a better way to predict venous thromboembolism risk in patients with lymphoma.

Major finding: The TiC-Lympho score for venous thromboembolism risk among lymphoma patients had a sensitivity of 93.55% and a specificity of 54.49%.

Study details: A retrospective study in 208 patients with lymphoma.

Disclosures: No conflicts of interest were reported.

Citation:

Pascual C et al. 2019 ISTH Congress, Abstract OC 41.3.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Lymphoma & Plasma Cell Disorders

Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplant,

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Study found dual-targeted CAR T highly active against relapsed/refractory multiple myeloma,

Phase 1 study shows feasibility, safety, efficacy of STAR T cells for ALL,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,